ANIK sentiment intelligence

Anika Therapeutics to issue Q2FY26 results on July 29

Anika Therapeutics, Inc. (NASDAQ: ANIK) is set to release its Q2FY26 financial results before the market opens on Wednesday, July 29, 2026. The company will host a conference call at 8:30 a.m. ET to discuss the results and provide business highlights. Investors can access the cal

Tone

Neutral 50/100

Event

Earnings

Published

15 Jul 2026 22:45

Source

scanx.trade

Anika to Issue Second Quarter 2026 Financial Results on Wednesday, July 29, 2026

Anika Therapeutics, Inc. (NASDAQ: ANIK) announced it will release its second quarter 2026 financial results before market open on Wednesday, July 29, 2026. A conference call will follow at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the live

Tone

Neutral 50/100

Event

Earnings

Published

15 Jul 2026 19:45

Source

GlobeNewswire

Anika sets July 29 conference call for second-quarter results

Anika Therapeutics, Inc. (NASDAQ: ANIK) announced it will release its second quarter 2026 financial results before market open on Wednesday, July 29, 2026. Following the release, management will host a conference call at 8:30 a.m. ET to discuss the results and business highlights

Tone

Neutral 50/100

Event

Earnings

Published

15 Jul 2026 19:45

Source

Stock Titan

Anika Therapeutics Enters Fifth Amendment To Credit Agreement - SEC Filing

Anika Therapeutics has announced that it has entered into a Fifth Amendment to its Credit Agreement. This information was disclosed in a recent SEC filing. The news was reported by Reuters.

Tone

Neutral 50/100

Event

Balance sheet

Published

14 Jul 2026 20:40

Source

TradingView

Anika Therapeutics (NASDAQ: ANIK) updates $50M revolving credit line terms

Anika Therapeutics (NASDAQ: ANIK) has updated the terms of its $50 million revolving credit line with Bank of America, N.A. through a Fifth Amendment to its Credit Agreement, extending the maturity date to July 10, 2031. The amended agreement allows for an additional $50 million

Tone

Neutral 50/100

Event

Balance sheet

Published

14 Jul 2026 20:40

Source

Stock Titan

Price to book forward of Anika Therapeutics Inc. – NASDAQ:ANIK

This article focuses on the "Price to book forward" metric for Anika Therapeutics Inc. (NASDAQ: ANIK). It presents financial data for the company across different periods, including value, change, and percentage change. The content appears to be a basic financial data display fro

Tone

Neutral 50/100

Event

Market update

Published

05 Jul 2026 08:11

Source

TradingView

Anika Therapeutics extends implant lifespan with engineered Hyaff for regenerative medicine

Tone

Neutral 50/100

Event

Market update

Published

01 Jul 2026 07:00

Source

Traders Union

ANIK Forecast — Price Target — Prediction for 2027

This article provides an overview of Anika Therapeutics Inc. (ANIK) stock performance, analyst forecasts, and various financial metrics. It includes the current stock price, historical highs and lows, analyst price targets, and details on recent earnings and revenue. The informat

Tone

Neutral 50/100

Event

Earnings

Published

25 Jun 2026 15:11

Source

TradingView

Director at Anika Therapeutics (ANIK) receives 10,402 RSU award, holding 58,273 shares

Anika Therapeutics director Richard Stephen was granted 10,402 restricted stock units (RSUs) on June 18, 2026. These RSUs vest in full by the earlier of the 2027 annual shareholder meeting or June 18, 2027. Following this award, Richard Stephen directly holds 58,273 shares of Ani

Tone

Neutral 50/100

Event

Market update

Published

23 Jun 2026 20:40

Source

Stock Titan

Director at Anika Therapeutics (ANIK) receives 10,402 RSUs equity grant

Anika Therapeutics director Joseph H. Capper received an equity grant of 10,402 Restricted Stock Units (RSUs) on June 18, 2026, increasing his direct holdings to 30,805 shares. These RSUs, granted at no cash cost, will vest in full on the earlier of the company's 2027 annual stoc

Tone

Neutral 50/100

Event

Balance sheet

Published

23 Jun 2026 20:39

Source

Stock Titan

Anika Therapeutics increases equity plan shares under amended omnibus and ESPP

Anika Therapeutics' board has approved amendments to its 2017 Omnibus Incentive Plan and 2021 Employee Stock Purchase Plan (ESPP), which will increase share reserves, pending stockholder approval at the 2026 Annual Meeting. The 2017 Plan will reserve an additional 350,000 shares,

Tone

Neutral 50/100

Event

Regulatory and legal

Published

23 Jun 2026 20:39

Source

TradingView

[Form 4] Anika Therapeutics, Inc. Insider Trading Activity

Anika Therapeutics director Sheryl L. Conley reported an acquisition of 10,402 restricted stock units (RSUs) of common stock as an equity award in a Form 4 filing. These RSUs vest fully on the earlier of the company's 2027 annual stockholder meeting or June 18, 2027. Following th

Tone

Neutral 50/100

Event

Deals and strategy

Published

23 Jun 2026 20:39

Source

Stock Titan

Director at Anika Therapeutics (NASDAQ: ANIK) receives 10,402 RSU grant

Anika Therapeutics director Gary P. Fischetti was granted 10,402 restricted stock units (RSUs), increasing his direct holdings to 52,015 shares. The RSUs, valued at $0.00 per share, encourage long-term alignment with shareholder interests by vesting fully on the earlier of the co

Tone

Neutral 50/100

Event

Market update

Published

21 Jun 2026 10:11

Source

Stock Titan

Anika Therapeutics Inc (ANIK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Anika Therapeutics Inc (ANIK) based on its business segments and geographical regions. As of April 6, 2024, the company's revenue is primarily driven by its OEM Channel (57.09%) and Commercial Channel (42.91%). Geographically

Tone

Neutral 50/100

Event

Earnings

Published

17 Jun 2026 20:08

Source

TradingKey

Anika Therapeutics Inc (ANIK) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Anika Therapeutics Inc's (ANIK) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and indicates no historical data for stock splits. The page also presents current stock pe

Tone

Neutral 50/100

Event

Capital return

Published

17 Jun 2026 19:08

Source

TradingKey

Anika Therapeutics Inc (ANIK) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis of Anika Therapeutics Inc (ANIK), noting its current valuation score of 8.58, ranking it 83 out of 203 in the Healthcare Equipment & Supplies industry. It highlights the company's P/E ratio of -18.06, which is significantly below its rece

Tone

Neutral 50/100

Event

Market update

Published

17 Jun 2026 10:40

Source

TradingKey

Anika Therapeutics Inc (ANIK) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Anika Therapeutics Inc (ANIK), detailing its current price momentum, support and resistance levels, and indicator readings. The analysis covers various technical indicators like MACD, RSI, and moving averages (MA5 to MA200), concludin

Tone

Neutral 50/100

Event

Market update

Published

17 Jun 2026 10:40

Source

TradingKey

Anika Therapeutics Inc (ANIK) Earnings Forecast: Future EPS & Revenue Growth Estimates

Anika Therapeutics Inc (ANIK) currently has an earnings forecast score of 9.00, placing it 4th in the Healthcare Equipment & Supplies industry. Analysts have a consensus "Strong Buy" rating for ANIK, with an average price target of $16.00. The company's expected revenue for the n

Tone

Neutral 50/100

Event

Earnings

Published

17 Jun 2026 10:40

Source

TradingKey

Anika Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Griffin Stephen D.

This document is a statement of changes in beneficial ownership of securities for Officer Griffin Stephen D. at Anika Therapeutics. It is filed as a Form 4, indicating a mandatory disclosure of transactions by company insiders.

Tone

Neutral 50/100

Event

Market update

Published

13 Jun 2026 13:10

Source

Moomoo

Anika reports inducement grants

Anika Therapeutics, Inc. announced that it granted restricted stock units (RSUs) covering 3,360 shares of common stock to a newly hired non-executive employee on June 1, 2026. This grant was made under the company's 2021 Inducement Plan and was approved by the compensation commit

Tone

Neutral 50/100

Event

Market update

Published

08 Jun 2026 11:09

Source

Medical Buyer